Managers / Q4 2022 · view latest →
Bellevue Group AG
CIK 0001674546 · THEATERSTRASSE 12, ZURICH, CH-8001 · 41 44 267 67 77
Reported Value
$7.53T
Q4 2022
Positions
215
Filings on Record
30
2019–present window
Filed
Feb 14, 2023
original filing
Summary
Bellevue Group Ag reported $7.53T in U.S.-listed holdings across 215 positions for Q4 2022.
Its largest position, ISI, represents 4.8% of the portfolio.
Compared with Q3 2022, the fund opened 8 new positions and exited 13.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
Composition data arrives with ticker enrichment.
Quarter-over-Quarter Changes full breakdown →
Holdings — Q4 2022
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $4.2B | 167 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $5.3B | 213 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $4.8B | 186 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $4.5B | 175 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $4.5B | 177 | May 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $5.2B | 193 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $6.2B | 196 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $6.2B | 204 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $6.6B | 208 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $6.5B | 202 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $6.2B | 196 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $7.0B | 198 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $6.9B | 202 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $7.53T | 215 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $7.0B | 217 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $7.1B | 214 | Aug 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $8.6B | 220 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $9.7B | 235 | Feb 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $9.9B | 265 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $10.2B | 262 | Aug 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $9.5B | 260 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $8.7B | 266 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $7.2B | 261 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $7.1B | 235 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $5.2B | 239 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $6.3B | 239 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $5.4B | 236 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $5.9B | 219 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $1.8B | 138 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $1.5B | 138 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 3 additional managers.
- BB Biotech AG28-06964
- Bellevue Asset Management AG28-16892
- Bellevue Asset Management (UK) Ltd.28-20408
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.